Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the wake of concern raised about the ethics and risks of performing genetic interventions in macaque monkeys to study models of human neuropsychiatric conditions, Professor Andrew Parker analyses how decision makers evaluate these situations and highlights the ethical consequences if research is not carried out.

As Darwin identified, genetic modification defines who and what we are biologically. In recent years, the technology of molecular biology has brought genetic modification under direct experimental control. We no longer have to wait for selective breeding to bring about changes in the genomes of ourselves or other organisms.

Andrew ParkerWhilst many experimental and translational programmes of research have employed this new technology, there was an unusual degree of outcry when a number of Chinese scientists successfully made somatic cell interventions in macaque monkeys. The technology is very similar to that used widely in DPAG for interventions in mice and flies.

In a new article, Professor Andrew Parker attempts to analyse some of the reasons why there was this degree of protest. In doing so, he also seeks to probe the ethical basis of judgements made by regulatory authorities. "I suggest there are fundamental weaknesses in the so-called “precautionary principle”, which is often advanced to justify the actions of review panels and administrative authorities." (Prof Parker).

"The ethical cost of doing nothing" is available to read in the National Science Review.

 

 

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.

Key exosome subtype in cancer progression identified

Collaborative work from DPAG and Oncology researchers has revealed a potential new pathway to block the production of a specific group of exosomes made in the cell’s recycling system that can promote the growth of cancerous tumours.

New blood test from DPAG cardiac researchers could save lives of heart attack victims

Researchers from the Herring group have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.